{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:29:43Z","timestamp":1793410183624,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Ophthalmology Practice and Research"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.aopr.2024.09.001","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T20:25:01Z","timestamp":1725395101000},"page":"220-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["An updated systematic review of pharmacological treatments for presbyopia"],"prefix":"10.1016","volume":"4","author":[{"given":"Andrzej","family":"Grzybowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6426-7616","authenticated-orcid":false,"given":"Laura","family":"Kapitanovaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"Zemaitiene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aopr.2024.09.001_bib1","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preteyeres.2018.09.004","article-title":"Presbyopia: effectiveness of correction strategies","volume":"68","author":"Wolffsohn","year":"2019","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"10.1016\/j.aopr.2024.09.001_bib2","first-page":"25","article-title":"Presbyopia treatment with eye drops: an eight year retrospective study","volume":"9","author":"Benozzi","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.aopr.2024.09.001_bib3","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.2147\/OPTH.S318065","article-title":"Presbyopia treatments by mechanism of action: a new classification system based on a review of the literature","volume":"15","author":"Chang","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.aopr.2024.09.001_bib4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.2147\/OPTH.S259011","article-title":"Presbyopia \u2013 a review of current treatment options and emerging therapies","volume":"15","author":"Katz","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"1643","key":"10.1016\/j.aopr.2024.09.001_bib5","first-page":"17","article-title":"Vuity - pilocarpine ophthalmic solution for presbyopia","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther"},{"key":"10.1016\/j.aopr.2024.09.001_bib6","unstructured":"An Evaluation of the Safety of CSF-1 in Presbyopic Subjects,\u201d Clinicaltrials.gov. Accessed: Mar. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05393895."},{"issue":"5","key":"10.1016\/j.aopr.2024.09.001_bib7","first-page":"1385","article-title":"Pharmacological treatment in presbyopia","volume":"11","author":"Grzybowski","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.aopr.2024.09.001_bib8","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.aopr.2024.09.001_bib9","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/APO.0000000000000297","article-title":"A\u00a0review of pharmacological presbyopia treatment","volume":"9","author":"Grzybowski","year":"2020","journal-title":"Asia-Pacific Journal of Ophthalmology"},{"issue":"12","key":"10.1016\/j.aopr.2024.09.001_bib10","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41433-020-01391-z","article-title":"Topical lipoic acid choline ester eye drop for improvement of near visual acuity in subjects with presbyopia: a safety and preliminary efficacy trial","volume":"35","author":"Korenfeld","year":"2021","journal-title":"Eye"},{"key":"10.1016\/j.aopr.2024.09.001_bib11","unstructured":"Novartis drops presbyopia drug acquired with Encore Vision,\u201d https:\/\/pharmaphorum.com\/. Accessed: March. 24, 2024. [Online]. Available: https:\/\/pharmaphorum.com\/news\/novartis-drops-presbyopia-drug-acquired-with-encore-vision."},{"key":"10.1016\/j.aopr.2024.09.001_bib12","unstructured":"Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS),\u201d Clinicaltrials.gov. Accessed: Mar. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05665387."},{"key":"10.1016\/j.aopr.2024.09.001_bib41","unstructured":"CLARITY Phase 3 Topline Results.\u201d Accessed: April. 15, 2024. [Online]. Available: https:\/\/ir.lenz-tx.com\/news-events\/presentations."},{"key":"10.1016\/j.aopr.2024.09.001_bib26","author":"Panarese"},{"issue":"1","key":"10.1016\/j.aopr.2024.09.001_bib30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0161-6420(79)35529-4","article-title":"Retinal detachments and topical ocular miotics","volume":"86","author":"Beasley","year":"1979","journal-title":"Ophthalmology"},{"key":"10.1016\/j.aopr.2024.09.001_bib23","unstructured":"Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia,\u201d Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05431543."},{"issue":"1","key":"10.1016\/j.aopr.2024.09.001_bib32","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/ICB.0000000000001309","article-title":"Rhegmatogenous retinal detachment after initiation of pilocarpine hydrochloride ophthalmic solution 1.25% for treatment of presbyopia","volume":"18","author":"Eton","year":"2024","journal-title":"Retin Cases Brief Rep"},{"issue":"7","key":"10.1016\/j.aopr.2024.09.001_bib33","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3928\/23258160-20220629-01","article-title":"Vitreofoveal traction associated with pilocarpine for presbyopia","volume":"53","author":"Amarikwa","year":"2022","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.aopr.2024.09.001_bib34","article-title":"Bilateral vitreomacular traction syndrome associated with topical pilocarpine 1% ophthalmic solution","volume":"30","author":"Rios Gonzalez","year":"2023","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"1","key":"10.1016\/j.aopr.2024.09.001_bib35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0161-6420(82)34866-6","article-title":"Side effects and ways to avoid them","volume":"89","author":"Zimmerman","year":"1982","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.aopr.2024.09.001_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40123-023-00648-6","article-title":"Non-miotic improvement in binocular near vision with a topical compound formula for presbyopia correction","volume":"12","author":"Vejarano","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.aopr.2024.09.001_bib37","unstructured":"Ocuphire Pharma announces submission of new drug application to FDA for Nyxol eye drops for reversal of mydriasis. News release.,\u201d Ocuphire Pharma. . Accessed: March. 30, 2024. [Online]. Available: https:\/\/www.ocuphire.com\/news-media\/press-releases\/detail\/393\/ocuphire-pharma-announces-submission-of-new-drug."},{"issue":"1","key":"10.1016\/j.aopr.2024.09.001_bib38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40662-016-0065-3","article-title":"Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia","volume":"3","author":"Abdelkader","year":"2016","journal-title":"Eye and Vision"},{"issue":"3","key":"10.1016\/j.aopr.2024.09.001_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/jop.1992.8.225","article-title":"Involvement of prejunctional alpha-adrenoceptor in bovine ciliary muscle movement","volume":"8","author":"Kubo","year":"1992","journal-title":"J\u00a0Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.aopr.2024.09.001_bib14","unstructured":"Pharmacological Treatment of Presbyopia,\u201d Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05564832#study-overview."},{"key":"10.1016\/j.aopr.2024.09.001_bib15","unstructured":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia (VEGA-2),\u201d Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/www.clinicaltrials.gov\/study\/NCT05646719."},{"key":"10.1016\/j.aopr.2024.09.001_bib16","unstructured":"Safety and Efficacy Study BRIMOCHOLTM PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia,\u201d Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05270863."},{"key":"10.1016\/j.aopr.2024.09.001_bib17","unstructured":"Efficacy of Pilocarpine 1% in Presbyopia,\u201d Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05578001."},{"key":"10.1016\/j.aopr.2024.09.001_bib18","unstructured":"Evaluation of the Safety and Effectiveness of Aceclidine\/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia,\u201d Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05294328."},{"key":"10.1016\/j.aopr.2024.09.001_bib19","unstructured":"\u201cPhase 3 Efficacy Study of LNZ101 for the Treatment of Presbyopia (CLARITY),\u201d Clinicaltrials.gov. Accessed: Mar. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05728944."},{"key":"10.1016\/j.aopr.2024.09.001_bib20","unstructured":"Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia,\u201d Clinicaltrials.gov. Accessed: Mar. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT06045299."},{"key":"10.1016\/j.aopr.2024.09.001_bib21","unstructured":"Phase 3 Safety Study for the Treatment of Presbyopia Subjects,\u201d Clinicaltrias.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05753189."},{"key":"10.1016\/j.aopr.2024.09.001_bib22","unstructured":"\u201cPhase 3 evaluation of the safety and efficacy of LNZ101 for the treatment of presbyopia (CLARITY),\u201d Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05656027."},{"key":"10.1016\/j.aopr.2024.09.001_bib24","unstructured":"Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia,\u201d Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT05936489."},{"key":"10.1016\/j.aopr.2024.09.001_bib25","unstructured":"\u201cSafety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia,\u201d Clinicaltrials.gov. Accessed: March. 24, 2024. [Online]. Available: https:\/\/clinicaltrials.gov\/study\/NCT06270030."},{"issue":"1","key":"10.1016\/j.aopr.2024.09.001_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/j.jcrs.0000000000001313","article-title":"Pilocarpine HCl 1.25% for treatment of presbyopia after laser vision correction: pooled analysis of two phase 3 randomized trials (GEMINI 1 and 2)","volume":"50","author":"Lievens","year":"2024","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.aopr.2024.09.001_bib28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ajo.2023.05.008","article-title":"Safety and efficacy of twice-daily pilocarpine HCl in presbyopia: the Virgo phase 3, randomized, double-masked, controlled study","volume":"253","author":"Kannarr","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.aopr.2024.09.001_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.clinthera.2023.12.005","article-title":"Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials","volume":"46","author":"Holland","year":"2024","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.aopr.2024.09.001_bib31","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ajo.2022.05.011","article-title":"Retinal detachments associated with topical pilocarpine use for presbyopia","volume":"242","author":"Al-khersan","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.aopr.2024.09.001_bib40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/jop.1998.14.363","article-title":"Selectivity of muscarinic agonists including (\u00b1)-Aceclidine and antimuscarinics on the human intraocular muscles","volume":"14","author":"Ishikawa","year":"1998","journal-title":"J\u00a0Ocul Pharmacol Therapeut"}],"container-title":["Advances in Ophthalmology Practice and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667376224000544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667376224000544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T18:43:14Z","timestamp":1732992194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667376224000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2667376224000544"],"URL":"https:\/\/doi.org\/10.1016\/j.aopr.2024.09.001","relation":{},"ISSN":["2667-3762"],"issn-type":[{"value":"2667-3762","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An updated systematic review of pharmacological treatments for presbyopia","name":"articletitle","label":"Article Title"},{"value":"Advances in Ophthalmology Practice and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aopr.2024.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Zhejiang University Press.","name":"copyright","label":"Copyright"}]}}